IQV Insider Trading

Insider Ownership Percentage: 1.60%
Insider Buying (Last 12 Months): $255,739.50
Insider Selling (Last 12 Months): $320,229.00

IQVIA Insider Trading History Chart

This chart shows the insider buying and selling history at IQVIA by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

IQVIA Share Price & Price History

Current Price: $153.59
Price Change: Price Increase of +3.455 (2.30%)
As of 04/29/2025 04:52 PM ET

This chart shows the closing price history over time for IQV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$150.16Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for IQVIA (NYSE:IQV)

89.62% of IQVIA stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IQV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$127Mbought$92MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5B$0$5BTotal InflowsTotal Outflows
IQVIA logo
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Read More on IQVIA

Today's Range

Now: $153.59
Low: $149.11
High: $153.98

50 Day Range

MA: $170.67
Low: $141.38
High: $194.71

52 Week Range

Now: $153.59
Low: $135.97
High: $252.88

Volume

676,074 shs

Average Volume

1,421,008 shs

Market Capitalization

$27.08 billion

P/E Ratio

20.48

Dividend Yield

N/A

Beta

1.46

Who are the company insiders with the largest holdings of IQVIA?

IQVIA's top insider shareholders include:
  1. Ari Bousbib (Insider)
  2. Eric Sherbet (Insider)
  3. Constantinos Panagos (Insider)
  4. Kevin C Knightly (Insider)
  5. John G Danhakl (Director)
Learn More about top insider investors at IQVIA.

Who are the major institutional investors of IQVIA?

IQVIA's top institutional shareholders include:
  1. Bank of New York Mellon Corp — 0.59%
  2. Sumitomo Mitsui Trust Group Inc. — 0.59%
  3. KBC Group NV — 0.34%
  4. Rhumbline Advisers — 0.26%
  5. Assenagon Asset Management S.A. — 0.23%
  6. GAMMA Investing LLC — 0.22%
Learn More about top institutional investors of IQVIA stock.

Which major investors are selling IQVIA stock?

Within the last quarter, IQV stock was sold by these institutional investors:
  1. Impax Asset Management Group plc
  2. Sequoia Financial Advisors LLC
  3. Handelsbanken Fonder AB
  4. Tran Capital Management L.P.
  5. Bank of New York Mellon Corp
  6. Allspring Global Investments Holdings LLC
  7. KBC Group NV
  8. Sumitomo Mitsui Trust Group Inc.

Which major investors are buying IQVIA stock?

Within the previous quarter, IQV stock was bought by institutional investors including:
  1. GAMMA Investing LLC
  2. Assenagon Asset Management S.A.
  3. Rhumbline Advisers
  4. Sawgrass Asset Management LLC
  5. Teacher Retirement System of Texas
  6. Marathon Asset Management Ltd
  7. Running Oak Capital LLC
  8. Calamos Advisors LLC